CompletedNCT00471588
Pramipexole or amisulpride for compulsive behavior in OCD and stimulant use
About this title
Read the official source — NCT00471588Medication studyAges 18–65United Kingdom
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- CambridgeSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateAugust 2006
- Recruitment status
- Completed
- Enrollment listed in the registry
- 52
- Sponsor
- GlaxoSmithKline
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United Kingdom
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00471588
- Official title
Show the full official title
Dopamine D2/D3 Receptor Agonist and Antagonist Drug Effects on Fronto-striatal Systems Related to Compulsive Behaviour in Healthy Volunteers and Patients With Addictive and Compulsive Disorders
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Cambridge
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is GlaxoSmithKline.
Did this study involve medication?
Yes. The study involved medication, including Pramipexole, Amisulpride.
Who was this study for?
Listed age limits: 18 years to 65 years.
Want to explore more studies?
Explore studiesRelated studies
A randomised controlled feasibility trial comparing clinical and cost effectiveness of cognitive behavioural therapy (CBT) and selective serotonin reuptake inhibitors (SSRI) and their combination i...
A randomised double-blind placebo-controlled pilot study of D-cycloserine-augmented exposure therapy in adolescents with OCD